title: [Retrospective analysis of the effect of vinpocetine infusion in ophthalmologic disorders].
abstract: Retrospective analysis of the effect of vinpocetine infusion in ophthalmologic disorders. The authors retrospectively examined the effect of vinpocetine infusion on various ophthalmological disorders. Based on the data of 280 patients they concluded that vinpocetine infusion has beneficial effects in numerous ophthalmologic disorders of vision and visual field. There was a clear difference regarding the response to treatment. Best results were achieved in diseases characterized by sclerosis, hypertonia and macular degeneration. The improvement was modest or progression was slowed in patients with nervus opticus ischaemia, glaucoma and myopia. These results are in accordance with the literature data. The beneficial effect of vinpocetine can be explained by the fact that the vessels of the eye are in direct connection with the cerebral circulation and hereby the circulation improving effect of vinpocetine could be effective. The neuronal effects of vinpocetine could also play a role at least in two ways. On the one hand by the direct effect exerted on the cells of retina (these cells are related to the neurons), and on the other hand by the improvement of the circulation and metabolism of the secondary visual cortex found in the occipital lobe (this effect is proved by PET studies).
authors.affiliation: Siófoki Városi Kórház, Szemészeti Osztály, Siófok, Budapest.
authors.forename: Sarolta
authors.initials: S
authors.lastname: Végh
authors.forename: Erzsébet
authors.initials: E
authors.lastname: Szikszay
authors.forename: Péter
authors.initials: P
authors.lastname: Bönöczk
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Cserjés
authors.forename: Gyöngyvér
authors.initials: G
authors.lastname: Kiss
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage; D003930:Diabetic Retinopathy / Q000188:drug therapy; D005128:Eye Diseases / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000188:drug therapy; D009798:Ocular Hypertension / Q000188:drug therapy; D018917:Optic Neuropathy, Ischemic / Q000188:drug therapy; D012174:Retinitis Pigmentosa / Q000188:drug therapy; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014748:Vinca Alkaloids / Q000008:administration & dosage*; D014786:Vision Disorders / Q000188:drug therapy; D014785:Vision, Ocular / Q000187:drug effects; D014794:Visual Fields / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D014748:Vinca Alkaloids; C013983:vinpocetine